NCT03518788 (Pleur-X) is a NA clinical trial of Pleur-X in Malignant Pleural Effusion, sponsored by Rolf Inderbitzi.

Who is sponsoring NCT03518788?

NCT03518788 is sponsored by Rolf Inderbitzi.

What drugs are being tested in NCT03518788?

Interventions in NCT03518788: Pleur-X, Pleurodesis.

What condition does NCT03518788 study?

NCT03518788 studies Malignant Pleural Effusion.

Is NCT03518788 still recruiting?

NCT03518788 is currently status unknown. Last updated 8 May 2018.

Last reviewed 2018-05-08 · How we verify

NCT03518788: Pleur-X

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Malignant Pleural Effusion: Pleur-X vs. Chemical Pleurodesis in VATS

Status unknown NA Last updated 8 May 2018

What this trial tests

NA trial testing Pleur-X in Malignant Pleural Effusion in 234 participants. Status unknown.

Timeline

25 January 2018

Primary endpoint
31 March 2020

31 December 2020

Quick facts

Lead sponsor	Rolf Inderbitzi
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	234
Start date	25 January 2018
Primary completion	31 March 2020
Estimated completion	31 December 2020
Sites	1 location across Switzerland

Drugs / interventions tested

Pleur-X
Pleurodesis

Conditions studied

Malignant Pleural Effusion — all drugs for Malignant Pleural Effusion →

Sponsor

Rolf Inderbitzi

Who can join

Adults 18 to 80, any sex, with Malignant Pleural Effusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective randomized study whose aim is to compare the efficacy of the permanent thoracic catheter (Pleur-X) versus chemical pleurodesis in videothoracoscopy (VATS) in the treatment of malignant pleural effusion at the first diagnosis.Patients with malignant pleural effusion for whom there is indication of surgery and who agree to participate in the study will be randomized 1: 1 in the Pleur-X arm (arm 1) or in the chemical pleurodesis arm (arm 2). The arm 1 provides for the installation of a permanent drainage under local anesthesia while the arm 2 provides a pleurodesis with talc in VATS under general anesthesia. Both procedures are standard of care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Malignant Pleural Effusion

Currently open trials in the same condition.

NCT06421610 — OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. · Phase 1 · recruiting
NCT05620329 — UNC Pleural Fluid Registry · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03518788 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rolf Inderbitzi
Last refreshed: 8 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03518788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing